Cell-Free Dot Blot as a Practical and Adaptable Immunoassay Platform for the Detection of Antibody Response in Human and Animal Sera

摘要

We describe a recently developed immunoassay platform based on the principles of cell-free synthetic biology and the dot-blot technique for customizable detection of antibody response in human and animal sera.

摘要

The string of global pathogenic outbreaks over the past two decades has highlighted the importance of serosurveillance strategies. Immunoassay platforms that serve to detect disease-specific antibodies in patients' sera are at the core of serosurveillance. Common examples include enzyme-linked immunosorbent assays and lateral flow assays; however, while these are gold standard methods, they require pathogen-specific consumables and specialized equipment, which limits their use outside of well-resourced laboratories.

We have recently developed a novel immunoassay platform called Cell-Free Dot-Blot (CFDB) and validated it using human and animal sera against SARS-CoV-2. Unlike conventional immunoassays, CFDB patient serum samples are immobilized to a solid phase (nitrocellulose membrane), while the target antigen is suspended in the mobile phase of the assay. To improve access to serosurveillance capabilities, CFDB antigens are produced on demand and with low-burden infrastructure using in vitro protein expression. Here, the antigen is fused with a peptide tag that can be detected using a single universal reporter protein for any CFDB assay. The result is that the CFDB does not require access to a multi-well plate reader or purified commercial molecular assay components. With these design considerations, CFDB addresses the shortcomings of existing immunoassay platforms by providing accessibility to non-centralized laboratories, adaptability for emerging pathogens, and affordability for lower-income communities.

In the current article, we will provide a step-by-step protocol to prepare and perform a CFDB immunoassay. Using our recent work on SARS-CoV-2 CFDB as an example, we will cover antigen DNA design for on-demand cell-free production, followed by preparation of the CFDB reporter protein, immobilization of serum samples on the solid phase, and finally, antigen-binding and detection steps of the assay. We anticipate that by following these instructions, researchers will be able to adapt the CFDB assay to detect immune responses in human and animal sera to any given pathogen.

引言

The COVID-19 pandemic revealed the critical need for affordable, scalable diagnostic tools, particularly for low-resource settings¹. Conventional immunoassays like enzyme-linked immunosorbent assays (ELISAs) have proven essential for detecting immune responses^2,3. However, their high cost, reliance on complex reagents, and dependence on specialized equipment limit their accessibility, especially during global health crises. In response to these challenges, we developed the Cell-Free Dot Blot (CFDB), a low-cost, adaptable immunoassay platform designed for the detection of anti-SARS-CoV-2 antibodies in human and animal sera.

CFDB leverages cell-free synthetic biology for the rapid, on-demand production of viral antigens using linear DNA templates^4,5. This eliminates the need for traditional cell-based cloning, expression, and purification processes, significantly speeding up antigen production while reducing costs. The CFDB method simplifies antibody detection by using a dot blot format, where sera are directly spotted onto nitrocellulose membranes. This system obviates the need for expensive multi-well plates and specialized lab equipment, allowing for a simple "dipping" workflow for incubation and wash steps. The platform also utilizes a SpyCatcher-SpyTag system, where a SpyCatcher2-Apex2 peroxidase chimera acts as a universal secondary detection reagent^5,6. This is produced using standard Escherichia coli-based expression, which eliminates dependence on costly commercial antibody conjugates. As a result, the CFDB system can perform serological assays with performance comparable to ELISAs at a significantly lower cost-about $3 USD per 96 sample assay compared to over $300 USD for a commercial ELISA kit⁵.

To demonstrate CFDB's effectiveness, we tested its ability to detect antibodies in precharacterized human and animal sera. Our results closely correlated with ELISA in identifying COVID-19-positive and -negative samples. In addition to human diagnostics, we evaluated CFDB's utility in animal models, testing sera from SARS-CoV-2-infected hamsters and those vaccinated with recombinant Nucleocapsid protein. These tests confirmed CFDB's potential for use in both human and veterinary diagnostics, making it a versatile tool for monitoring immune responses across species. One of the key advantages of CFDB is its flexibility. By simply modifying the DNA template encoding the antigen of interest, the platform can be rapidly adapted to detect antibodies against different pathogens, making it valuable for future pandemic preparedness. Its low cost, simple workflow, and minimal infrastructure requirements make it particularly suitable for decentralized laboratories and low-resource environments, where access to commercial diagnostics is limited.

In this work we will provide step-by-step instructions for preparing and conducting a CFDB assay. First, we cover the design and synthesis of linear DNA templates for cell-free production of antigens, which are the assay's primary detection reagents. We then describe steps for the preparation of the assay's secondary detection reagent SpyCatcher2-Apex2. After that, we provide instructions for the cell-free production and quality-check of antigens themselves. Finally, we describe in detail the process for conducting a CFDB assay on human or animal serum samples.

方案

All hamster experiments were performed at the National Microbiology Laboratory (NML) at the Public Health Agency of Canada, approved by the Canadian Science Centre for Human and Animal Health, and following the Canadian Council on Animal Care guidelines. All human serum/plasma samples were obtained commercially for in-house testing or provided by clinical collaborators to the NML for independent testing at the NML.

1. Design and preparation of antigen linear expression templates (LETs)

1. Design the cell-free expression LETs for the target antigen based on the instructions in Norouzi et al.⁷ and containing an N/C-terminal SpyTag as described in Norouzi et al.⁵.
   NOTE: Here we provide details for the preparation of SARS-CoV-2 Nucleocapsid Protein (NP, amino acids 2-419).
   1. Ensure that the LET for the SARS-CoV-2 NP (Figure 1 and Supplemental File 1) contains 5' and 3' Ter sites with a 50 base pair buffer sequence before the T7 promoter and after the stop codon.
   2. Tag the NP protein on the N-terminus with His₆-SpyTag-TEV.
   3. Obtain the protein sequence from the UniProt Database (Accession Code P0DTC9) and codon-optimize it for E. coli-based expression using the IDT codon optimization tool⁸. Order this sequence for commercial synthesis as a single-stranded DNA fragment resuspended in water at 10 ng/μL.
      NOTE: The TEV protease cleavage site and the His₆ tag are not essential features in the LET design.
2. PCR amplify the DNA fragment with the universal Ter FW (GGCTCCGAATAAGTATGTTGTAACTAAAGTGCGGCC
   ACGATGCGTCCGGCGTAGAGGATCG) and Ter RV (CCGAGGCAATAAGTATGTTGTAACTAAAGTGCTCAG
   CTTCCTTTCGGGCTTTGTTAGCAGCC) primers using the high-fidelity DNA polymerase kit (see the Table of Materials)
   1. Set up a 100 µL reaction as follows: 75 µL of nuclease-free water, 20 µL of 5x DNA polymerase buffer, 2 µL of 10 mM dNTPs (final concentration 200 µM), 0.5 µL of 100 µM Ter-FW primer, 0.5 µL of 100 µM Ter-RV primer, 1 µL of 10 ng/µL single-stranded LET, 1 µL(2U) of DNA polymerase.
   2. Use the following PCR settings: initial denaturation at 98 °C for 30 s; 35 cycles: 98 °C for 6 s, 60 °C for 15 s, 72 °C for 90 s; hold at 4 °C.
3. Purify the PCR product using a commercial PCR purification kit, check its quality by running a sample on a 1% agarose gel, and measure its concentration on a UV-Vis spectrophotometer.
   NOTE: Crude PCR products can also be used directly for cell-free expression. However, purification allows for a more standardized procedure.

Figure 1: Linear expression template for SARS-CoV-2-NP. A schematic representing features of the His-SpyTag-SARS-CoV-2 NP linear DNA template. Key DNA template elements are labeled. The coding sequence for the protein of interest, here the NP, is placed under the transcriptional control of a T7 promoter for efficient expression. At the N-terminus, the NP protein is appended with a SpyTag for specific detection using the SpyCatcher2-Apex2 detection reagent. The x6His-tag and TEV protease sites, although included as part of the general LET design, are dispensable for CFDB purposes. At the termini of the linear DNA template, "upstream" and "downstream" Ter sites, each preceded by respective 50 base pair buffer sequences, are included for Tus-mediated protection against exonucleolytic DNA degradation in the cell-free lysate. Abbreviations: NP = nucleocapsid protein; LET = linear expression template; TEV = tobacco etch virus; CFDB = cell-free dot blot. Please click here to view a larger version of this figure.

2. Purification of the SpyCatcher2-Apex2 reporter protein

1. Use the pET24b-SpyCatcher2-Apex2 plasmid, originally constructed in Norouzi et al.⁵ (full sequence in Supplemental File 2 and plasmid map in Supplemental Figure S1) to prepare the SpyCatcher2-Apex-2 reporter protein.
2. Prepare agar plates and lysogeny broth (LB) containing 50 μg/mL kanamycin. Transform E. coli BL21 (DE3) cells with the pET24b-SpyCatcher2-Apex2 plasmid. Inoculate a single colony into a 15 mL starter LB culture and grow overnight at 37 °C with shaking at 250 RPM.
3. Next day, add 10 mL of the starter culture into 500 mL of fresh LB media containing 50 μg/mL kanamycin. Incubate at 37 °C with shaking at 250 RPM until the culture reaches an optical density at 600 nm of 0.6-0.8 (~3 h).
4. Induce the expression of SpyCatcher2-Apex2 by supplementing the culture with 0.5 mM isopropyl-β-D-1-thiogalactopyranoside and 1 mM 5-aminolevulinic acid hydrochloride. Reduce the growth temperature to 30 °C and allow the culture to incubate for another 4 h.
5. Harvest the bacteria by centrifugation at 8,000 × g for 15 min. Proceed to cell lysis or alternatively store the pellet at -80 °C until use.
6. Resuspend the pellet in 20 mL of lysis buffer containing 50 mM Tris-HCl (pH 7.8), 300 mM NaCl, 1 mg/mL lysozyme, EDTA-free protease inhibitor tablet, and 1 mM dithiothreitol (DTT). Lyse the cells by sonication at 50 % amplitude with 5 s ON and 10 s OFF intervals for a total ON time of 3 min.
7. Clarify the lysate by centrifugation at 20,000 × g for 1 h at 4 °C. Pass the supernatant through a 0.2 μm syringe filter.
8. Add hemin chloride to a final concentration of 250 μM to the clarified lysate and incubate overnight at 4 °C. Proceed to protein purification.
   NOTE: Incubation with hemin chloride maximizes heme incorporation into the Apex-2 peroxidase for optimal enzyme activity.
9. Add 2.5 mL of Ni resin to the clarified lysate and incubate at 4 °C with gentle shaking for 45 min. Apply the mixture to a gravity flow column and wash the resin with 50 mL of Tris buffer (50 mM Tris-HCl (pH 7.8), 300 mM NaCl, and 1 mM DTT).
10. Elute the SpyCatcher2-Apex2 protein in 25 mL of Tris buffer containing 400 mM imidazole. Concentrate and buffer exchange the eluate into Tris buffer using a centrifugal filter unit, aiming for a final volume of 0.5-1.0 mL.
11. Use the molar extinction coefficient of SpyCatcher2-Apex2 (27,390 M^-1 cm^-1) to determine the protein concentration on a UV-Vis spectrophotometer. Add glycerol to a final concentration of 40% and store the aliquots at -20 °C.
    NOTE: This protocol is expected to yield approximately 40 mg of highly pure and active SpyCatcher2-Apex2, sufficient for 400 CFDB runs on a standard 96-sample blot size.
12. For detection of SpyTagged proteins using conventional western blot⁹ and for CFDB experiments, always block membranes in 5% non-fat dry milk in 1x Tris-buffered saline containing 0.05% Tween-20 (TBST). Use the SpyCatcher2-Apex2 protein at a final concentration of 10 μg/mL in blocking solution.
    NOTE: The SpyCatcher2-Apex2 reporter requires enhanced chemiluminescence (ECL) solution for signal development. The ECL solution can be obtained commercially or prepared in-house according to instructions in Mruk et al.¹⁰. The final ECL solution here consists of 0.4 mM p-coumaric acid, 2.5 mM luminol, and 0.015% H₂O₂ in 100 mM Tris-HCl (pH 8.6).

3. Cell-free production and quality check of antigens

1. Prepare and assemble an E. coli BL21 cell-free expression lysate and reaction components by following the instructions in Levine et al.¹¹ and Norouzi et al.⁵. Supplement the final reaction mixture with 5 μM Tus protein and 1.2 μM T7 RNA Polymerase as follows for a representative 100 μL reaction: 14.6 µL of Solution A, 14 µL of Solution B, 33.3 µL of E. coli BL21 lysate, 2.5 µL of 200 mM Tus protein, 1.2 µL of 100 mM T7 RNA polymerase, 1 µL of 1.5 µM linear DNA template, 33.4 µL of nuclease-free water.
   NOTE: See Supplemental File 3 for key instructions on preparing an E. coli BL21 cell-free lysate and Supplemental Table S1 for a detailed recipe of Solutions A and B. The E. coli cell-free expression system can also be prepared using alternative protocols or obtained commercially, as long as the reaction is supplemented with Tus and T7 RNA Polymerase.
2. Perform an initial 5 μL-scale expression test by adding 10% (v/v) crude PCR product to the cell-free reaction in a PCR tube. Incubate without shaking at 30 °C for 15 h.
3. Check the expression quality of the NP antigen by loading 1 μL of the cell-free reaction on a 12% sodium dodecyl sulfate polyacrylamide gel (SDS-PAGE) and subsequently transfer it to a nitrocellulose membrane for western blot as described in step 2.12. Use the SpyCatcher2-Apex2 reporter protein for blot labeling via the SpyTag, and optionally, a specific commercial antibody (here an anti-SARS-CoV-2-NP) against the target antigen.
4. Assemble a 1 mL-scale cell-free reaction with 15 nM purified LET product to be used for the CFDB assay. Incubate the expression mixture in a 15 mL conical tube with shaking at 80 RPM for 15 h at 30 °C. Check the expression quality using western blot and store 50 μL aliquots at -20 °C.

4. Serum samples

1. Obtain human/animal serum (or plasma) samples from commercial sources or clinical collaborators or in-house using standard procedures and following guidelines from institutional human research ethics committee or animal care and use committee. Ensure that appropriate sample pretreatment measures have been taken to mitigate risks of contamination.
   NOTE: Pretreatment measures may include solvent-detergent treatment, heat inactivation, and testing for bloodborne virus markers. A useful protocol for serum and plasma isolation from whole blood is available¹². As with other immunoassay platforms, serum samples collected early (<3 weeks) after initial infection or disease onset are not expected to contain adequate levels of an antibody response and their results should be treated with caution.
2. For quality verification of the SARS-CoV-2 NP CFDB reagents, use The National Institute for Biological Standards and Control (NIBSC) World Health Organization (WHO) international reference panel for anti-SARS-CoV-2 immunoglobulin, which contains x1 pre-COVID-19 and x4 SARS-CoV-2-positive samples with varying levels of anti-NP immunoglobulins¹³. Alternatively, use precharacterized healthy and positive serum samples from other sources.
3. For CFDB experiments, obtain or prepare a negative control sample by pooling multiple (>3) healthy serum samples to increase the accuracy and facilitate the analysis and interpretation of results.

5. Cell-free Dot Blot (CFDB) procedure

1. Download and print the master-grid image file (Supplemental Figure S2). The master grid is a 6 x 6 cm pattern containing 12 x 12 circles of 2 mm diameter each and provides a spotting capacity similar to a 96-well plate.
2. Sandwich the grid firmly between two layers of adhesive PCR plate sealing film and cut to size along the outer grid borders. Use a 2 mm biopsy punch to hollow each marked circle.
   NOTE: This master grid can be reused multiple times after wiping with 70% ethanol.
3. Cut a 6.5 x 6.5 cm piece of nitrocellulose membrane and position it under the master grid on a clean surface, securing the setup using adhesive tape as shown in Figure 2 and Supplemental Figure S3. Use a marker pen to mark the outermost circle positions on the nitrocellulose membrane to be used as a guide to cut the membrane after sample spotting.
4. Dilute the serum samples 1/10 in 1x phosphate-buffered saline (pH 7.4). Use a micropipette to dispense triplicate 0.4 μL volumes of each sample onto the nitrocellulose membrane at predetermined grid positions. It will take approximately 15 s per spot to dispense.
   NOTE: Be sure to include both negative and positive control samples with each assay, as this will be required for the analysis of results.
5. Allow 10 min at ambient temperature for the spotted samples to bind and dry. Using tweezers, carefully retrieve the nitrocellulose membrane and cut along the marked outer circles.
6. Block the membrane in 10 mL of blocking solution (5% non-fat dry milk in TBST) in a 10 cm Petri dish for 30 min at room temperature, shaking gently at 100 RPM.
7. Thaw and add a 50 μL aliquot of the cell-free antigen expression mixture to 5 mL of blocking solution in a 10 cm Petri dish. Transfer the membrane directly to this antigen-containing solution and incubate at room temperature for 1 h, shaking at 100 RPM.
   NOTE: This will be the primary detection step where the SpyTagged antigen will bind to antibody-containing spot positions, if present.
8. Rinse the membrane, wash for 5 min, and rinse again in TBST before proceeding to the secondary detection step.
9. Incubate the membrane in 10 mL of blocking buffer containing 10 μg/mL of purified SpyCatcher2-Apex2 protein, for 1 h while shaking at 100 RPM.
10. Rinse the membrane and wash 2 x 5 min in TBST, with a final rinse in TBS.
11. Stick and secure a piece of parafilm on a clean work area close to the blot imaging instrument. Remove excess liquid by tapping the membrane using tweezers and place the membrane on top of the parafilm.
12. Immediately add 3 mL (100 μL/cm²) of ECL solution on top of the membrane and incubate at room temperature for exactly 90 s.
13. Immediately tap-dry the membrane and transfer to a chemiluminescence-compatible imaging instrument for visualization of results.
    NOTE: Optimal imaging time can vary on different instruments. It is recommended to use the instrument's default auto-acquisition time settings, and if absent, use precharacterized serum samples to optimize image acquisition time.
14. Use the instrument's image analysis function to obtain spot intensities, including for three blank (background) positions on the nitrocellulose membrane; maintain a constant measurement volume per spot. Export the data to a spreadsheet, remembering to correctly label each spot position.
15. Calculate the Mean and Standard Deviation (SD) of triplicate spot intensities. Then, subtract the nitrocellulose membrane background from all samples.
16. Use the following equation to obtain a cut-off value for the interpretation of -/+ results:
    (Mean of negative controls) + (3 x SD of the negative controls). Consider samples positive if their average intensity falls above the cut-off value and negative if their average intensity falls below the cut-off value.
    ​NOTE: A schematic of the CFDB procedure is provided in Figure 3.

Figure 2: CFDB assembly. A schematic of the CFDB master grid and NC membrane assembly setup. The master grid is overlaid on the NC membrane to provide a regular, addressable pattern for spotting and immobilization of serum samples. Abbreviations: CFDB = cell-free dot blot; NC = nitrocellulose. Please click here to view a larger version of this figure.

Figure 3: A schematic representation of the CFDB workflow. In a CFDB assay, a small amount (<0.4 μL) of 10x diluted serum samples is manually dispensed onto a precut nitrocellulose membrane (left panel) in discrete, addressable locations (middle panel). Depositing one serum sample per spot in triplicate spots and immobilizing the protein content, including the sera's total antibody reservoir, on the solid NC substrate (beige spots in the middle panel). In this example, anti-NP antibodies contained in the serum samples can be first bound by the CFDB primary detection reagent SpyTag-NP and finally detected by the CFDB secondary detection reagent SpyCatcher2-Apex2 (right panel-magnified bubble). This figure was taken from Norouzi et al.⁵. Abbreviations: CFDB = cell-free dot blot; NP = nucleocapsid protein; LET = linear expression template. Please click here to view a larger version of this figure.

结果

PCR amplification of the linear expression template for target antigen
To PCR-amplify the SARS-CoV-2 NP LET, universal Ter forward and reverse primers were used as described in protocol section 1.2 and 1 μL of the product was checked on an agarose gel (Figure 4) before proceeding to the purification of the PCR product.

讨论

COVID-19 highlighted the importance of accessible and robust diagnostics for controlling infection outbreaks and optimizing global health strategies. Serological testing that detects protective antibodies proved essential for tracking transmissibility patterns of new variants, identifying hot spots, guiding vaccine development, triaging suspected cases and protecting vulnerable populations¹⁴. The pandemic also exposed inequities in testing accessibility, exasperated by backlogs and requirements fo...

材料

本文使用的材料清单

姓名	公司	目录编号	评论
1 kb DNA 分子量标准	NEB	N3232	用作琼脂糖凝胶的大小标记物
20 个氨基酸	Sigma-Aldrich	LAA21-1KT	无细胞反应的组分 溶液 B
2 mm 活检穿刺器	Integra Miltex	33-31-P/25	用于制备 CFDB 主网格
5-氨基乙酰丙酸盐酸盐	Sigma-Aldrich	A3785	用于诱导 SpyCatcher2-Apex2 琼脂糖粉末的血红素前体
	BioShop	AGA002
抗 SARS-CoV2-核衣壳抗体	Sinobiological	40588-T62	用于无细胞产生的 NP 抗原的 WB 检测
Bio-Rad ChemiDoc XRS+	Bio-Rad	N/A	凝胶成像仪
离心浓缩器	Cytiva	28-9323-60	用于蛋白质的浓缩和缓冲液交换
离心	Eppendorf	EP022628257	用于收获细菌培养
物 辅酶 钠盐水合物 （CoA）	Sigma-Aldrich	C3144	无细胞反应溶液的组分 A
彩色预染蛋白标准品（范围广）	NEB	P7719	用作 SDS-PAGE 凝胶的尺寸标记
Covid-19 血清面板	RayBiotech	CoV-PosSet	用于验证和优化 CFDB 试剂/条件
的预表征血清D-（&-us;）-3-磷酸甘油酸二钠盐 （3-PGA）	Sigma-Aldrich	P8877	A 无细胞反应组分 溶液 B
二硫苏糖醇 （DTT）	Sigma-Aldrich	10197777001	缓冲液组分
大肠杆菌 5-α	NEB	C2987	用于质粒制备
大肠杆菌 BL21	NEB	C2530	用于制备游离裂解物
大肠杆菌 BL21 （DE3）	NEB	C2527	用于 SpyCatcher2-Apex2 的表达
不含 EDTA 的蛋白酶抑制剂片	Sigma-Aldrich	11836153001	大肠杆菌裂解缓冲液
Eppendorf 的一种成分 新不伦瑞克省 Innova 43/43R 培养箱摇床	Eppendorf	EPM1320	培养箱，用于培养大肠杆菌细胞，用于蛋白质表达和无细胞裂解物制备
亚叶酸	Sigma-Aldrich	47612	无细胞反应溶液的组分 甘
油	Sigma-Aldrich	G9012	SpyCatcher2-Apex2 储存缓冲液组分
血红素氯化物	Sigma-Aldrich	H9039	用于 SpyCatcher2-Apex2 的血红素补充剂
过氧化氢 30%	Sigma-Aldrich	H1009	用于制作 ECL 试剂
图像实验室软件	用于 ChemiDoc 凝胶的 Bio-Rad	1709690	软件  成像仪器
异丙基-b-D-1-硫代吡喃半乳糖苷	Bioshop	IPT001	用于诱导 SpyCatcher2-Apex2 expressikon
硫酸卡那霉素	Sigma-Aldrich	60615	用于制备 SpyCatcher2-Apex2 细菌培养
物 LB 琼脂	BioShop	LBL406	用于大肠杆菌生长
LB 肉汤	BioShop	LBL407	用于大肠杆菌生长
鲁米诺	Sigma-Aldrich	A4685	用于制备 ECL 试剂
菌酶	Sigma-Aldrich	L6876	用于裂解细菌细胞
乙酸镁	Sigma-Aldrich	M5661	无细胞反应的组分 溶液 B
NEBExpress Ni 树脂	NEB	S1428S	用于纯化 SpyCatcher2-Apex2
脱脂奶粉	Bioshop	SKI400	用于封闭 WB 和 CFDB 膜
封口膜	Bemis	2099-1337410	用于 CFDB 印迹的 ECL 孵育
p-香豆酸	Sigma-Aldrich	C9008	用于制备 ECL 试剂
pET24b-SpyCatcher2-Apex2 质粒	Pardee 实验室	N/A	用于表达 SpyCatcher2-Apex2 蛋白
培养皿	Fisherbrand	FB0875712	WB 和 CFDB 膜孵育容器
磷酸盐缓冲盐水 10%	BioShop	PBS405	缓冲液组分
谷氨酸钾	Sigma-Aldrich	G1501	无细胞反应的组分 溶液 B
草酸钾一水合物（草酸）	Sigma-Aldrich	223425	无细胞反应的组分 溶液 A
预制 SDS-PAGE 凝胶	BioRad	4561036EDU	用于蛋白质
Q5 高保真 DNA 聚合酶	NEB	M0491	用于 LET 的 PCR 扩增
QIAquick PCR 纯化试剂盒	Qiagen	28106	用于纯化 LETs
核糖核苷酸溶液套装	NEB	N0450S	无细胞反应溶液 A
脱脂奶粉	BioShop	SKI400	用作蛋白质印迹和 CFDB 的封闭剂
氯化钠	Sigma-Aldrich	S9625	蛋白质纯化缓冲液的组分
Sonicator	Qsonica	Q500	用于裂解细菌细胞
亚精胺	Sigma-Aldrich	S2626	无细胞反应的组分 溶液 A
针式过滤器	Sigma-Aldrich	SLGSR33SS	用于缓冲液和溶液的灭菌
热循环仪	BioRad	T100	培养 PCR 反应的仪器
转移 RNA （tRNA）	Sigma-Aldrich	R8759	无细胞反应溶液的一种组分
Tris 缓冲盐水	Thermo Scientific	J60764。K2	WB 和 CFDB 洗涤缓冲液的组分
Trizma 碱	Sigma-Aldrich	T1503	用于制备 tris 缓冲液
Tunair SS-5012 半挡板摇瓶，2.5 L	Cole-Parmer	RK-01835-39	用于培养大肠杆菌细胞的容器，用于蛋白质表达和无细胞裂解物制备
Tween-20	BioShop	TWN510	WB 和 CFDB 洗涤缓冲液的组分
镊子	Almedic	7728-A10-100	用于处理 CFDB NC 膜
紫外-可见分光光度计	Thermo Scientific	13400518	用于测量核酸和 DNA 浓度以及细菌培养物 OD
WHO 抗 SARS-CoV-2 免疫葡萄糖素国际参考小组	NISBC	20/268	用于验证和优化 CFDB 试剂/条件
的预表征血清&β;-烟酰胺腺嘌呤二核苷酸水合物 （NAD）	Sigma-Aldrich	10127965001	无细胞反应溶液 A 的组分